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Mucosal  melanoma  of  the  nasal  cavity  and paranasal  sinuses  is a  rare  disease,  but  its incidence  appears
to  be increasing.  The  mean  age at diagnosis  is  between  65  and  70 years.  Unilateral  nasal  obstruction
and  epistaxis  are  the most  common  presenting  complaints.  Melanoma  arises  in  the  septum  or  lateral
wall  of the  nasal  cavity  in the  great  majority  of  cases.  The  histological  diagnosis  is  based on  speciﬁc
immunohistochemical  labelling  and  is  usually  established  at  an advanced  stage  of  disease:  stage  T3  or
T4  tumours  according  to the  7th  edition  of  the American  Joint  Committee  on  Cancer  (AJCC)  classiﬁcation
of  tumours.  First-line  treatment  consists  of surgery.  The  place  of  intranasal  endoscopic  surgery  remains
controversial  due  to the  difﬁculty  of  controlling  surgical  margins  and  should  be  reserved  for  experienced
teams.  Adjuvant  radiotherapy  is usually  performed  due  to its efﬁcacy  on  local  and  regional  disease  control.
Five-year  overall  survival  of mucosal  melanoma  of  the  nasal  cavity  and  paranasal  sinuses  in the most
recent  series  does  not  exceed  40%.  Local  recurrence  is  observed  in  about  50%  of cases  and  metastatic
disease  is  common.  The  quality  of  initial  tumour  resection  with  negative  surgical  margins  is  the  most
important  prognostic  factor  for tumours  conﬁned  to the  nasal  cavity.  Hopes  for  improvement  of  survival
are  based  on  early  diagnosis,  progress  in  radiotherapy  techniques  and  cell  and  gene  therapy  that  are
currently  under  evaluation.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Primary mucosal melanoma of the nasal cavity and paranasal
inuses is a rare tumour [1,2]. Positive diagnosis of this tumour is
ade difﬁcult by the non-speciﬁc presenting complaints [3,4]. This
umour has a poor prognosis due to its aggressive nature and the
requently delayed diagnosis. It mainly occurs in the elderly and
he presence of comorbidities can limit the extent of treatment
4]. Treatment options essentially consist of radical surgery and
adiotherapy, while chemotherapy is reserved for advanced forms.
espite a better knowledge of this tumour, the 5-year overall sur-
ival remains poor and does not exceed 40% in any of the published
tudies [5–8].
. Pathogenesis and epidemiology.1. Pathogenesis
Melanocytes are dendritic cells arising in the neural tube and
ocated at the dermo-epidermal junction of all mucous membranes.
∗ Corresponding author.
E-mail address: lgilain@chu-clermontferrand.fr (L. Gilain).
http://dx.doi.org/10.1016/j.anorl.2013.11.004
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.The presence of melanocytes in the mucosa of the nasal cavity and
paranasal sinuses has been known for a long time. Melanocytes
are detected under normal conditions in about 21% of individ-
uals [3]. Mucosal melanoma is a neuroectodermal tumour arising
from these melanocytes [3,9]. A higher density of melanocytes in
the mucosa of the nasal cavity and paranasal sinuses compared to
other sites could explain the relative frequency of primary mucosal
melanomas in this site [5]. No risk factor has been clearly identi-
ﬁed to explain the development of these tumours. In contrast with
melanoma of the skin, in which sun exposure is known to be the
major risk factor, the risk factors for mucosal melanomas have not
been identiﬁed. No link has been demonstrated between Human
Papilloma Virus (HPV) or Herpes virus in the aetiopathogenesis of
mucosal melanoma [3]. Exposure to formaldehyde has been sus-
pected but not conﬁrmed in several studies [3,10]. Smoking may
constitute a predisposing factor essentially for mucosal melanoma
of the oral cavity [3,11]. Several genetic studies have demonstrated
gene mutations affecting the tyrosine kinase receptor [3,12]. Some
authors have suspected the role of heredity and environment in the
pathogenesis of mucosal melanoma in order to explain the differ-
ent prevalence rates of these tumours between Caucasian (1% of
melanomas) and Asian populations (7.5% of melanomas) [1,5].
Casiraghi and Lefèvre considered that mucosal melanomas of
the nasal cavity and paranasal sinuses were histologically related
to the group of malignant round cell tumours [13]. They suggested
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3.4. Imaging
An imaging assessment comprising computed tomography (CT)
of the facial bones and magnetic resonance imaging (MRI) is an66 L. Gilain et al. / European Annals of Otorhinolary
 morphological continuum of these tumours between the two
xtremes of life, with sarcomas in children and young adults and
ucosal melanoma in the elderly [13].
.2. Epidemiology
Primary mucosal melanoma of the nasal cavity and paranasal
inuses is a rare tumour, representing between 0.7 and 1% of
ll melanomas in Caucasian populations and between 4 and 8%
f malignant tumours of the nasal cavity and paranasal sinuses
3,14]. The incidence of mucosal melanoma appears to be increas-
ng, especially in the nasal cavity and paranasal sinuses [2,15]. This
ncreasing incidence appears to be signiﬁcant in women [2,14,15].
espite this increase, the prevalence currently remains identical
n the two sexes [4]. The patient’s age at the time of diagnosis is
etween 60 and 80 years with a mean age between 65 and 70 years
5,16]. Primary mucosal melanoma can arise in various anatomi-
al sites, but it predominantly (55% of cases) involves the head and
eck [5], in which the nasal cavity and paranasal sinuses is the most
requent site, representing 70% of cases (50% in the nasal cavity, 20%
n the paranasal sinuses) followed by the oral cavity in about 17%
f cases [2].
. Diagnosis and assessment
.1. Clinical features
The most common presenting complaints are nasal obstruc-
ion and epistaxis. Nasal obstruction is unilateral, permanent and
rogressive, either isolated or associated with other symptoms.
pistaxis can be abundant or minimal with the presence of streaks
f blood when blowing the nose [4,17]. Some authors have reported
pistaxis to be the most common presenting complaint [6]. These
on-speciﬁc symptoms are often considered to be responsible
or the long interval between ﬁrst symptoms and diagnosis of
elanoma. This is particularly true when the tumour arises in the
aranasal sinuses [7]. Other symptoms include rhinorrhoea which
an be purulent in the case of superinfection, pain and lacrimation
n the case of invasion of the inferior meatus and lacrimal duct. More
dvanced tumours may  present in the form of malar swelling, nasal
eformity or exophthalmos.
.2. Clinical examination
Unilateral symptoms must be considered to be suspicious and
ustify thorough ﬁbroscopic or endoscopic investigation of the
asal cavity. Intranasal examination deﬁnes the appearance of the
umour (sessile, nodular, polypoid or granulating), its size and
mplantation. It may  be slate-coloured, reddish, crimson, brownish
r black, which is highly suggestive of the diagnosis. The tumour
urface can be homogeneous or heterogeneous, with a friable con-
istency and the tumour may  be covered by a greyish exudate. An
lcerated appearance is frequently observed [3,13]. One-third of
elanomas are achromic [4]. The exact origin of the tumour is
ometimes difﬁcult to determine and the tumour is often already
xtensive at the time of diagnosis with a mean diameter ranging
etween 2 and 3 cm [14]. Tumours of the nasal cavity predom-
nantly involve the septum and lateral wall, while tumours of
he paranasal sinuses predominantly involve the maxillary sinus
ollowed by the ethmoid, frontal and sphenoidal sinuses [4,5].
he cranial nerves must be systematically examined looking for
culomotor disorders and sensory loss of the face. Complete clini-
al staging assessment must include palpation of regional lymph
odes. At the time of diagnosis of the primary tumour, cervi-
al lymph node metastases are detected in 10 to 20% of patients
1,13,17] and haematogenous metastases are detected in 6% ofFig. 1. Inﬁltration of the mucosa of the nasal cavity by melanoma. The arrow indi-
cates the cellular proliferation invading the mucosa underneath an intact surface
epithelium.
patients (lungs, brain, bone, liver) [13]. A complete dermatological
and ophthalmological examination must be performed to detect a
possible primary tumour in order to conﬁrm the primary or sec-
ondary nature of the tumour of the nasal cavity and paranasal
sinuses.
3.3. Histology
The diagnosis is based on histological examination of tumour
biopsies. Histological examination is difﬁcult due to marked
cytological and architectural polymorphism [4]. The presence of
intracytoplasmic melanin pigment can be detected by the afﬁnity
for Fontana stain [13,17] (Figs. 1 and 2). Several parameters are
evaluated on histological examination: morphology and cellular
architecture, pigmentation, presence of ulceration, percentage of
necrosis, number of mitoses, inﬂammation and bone, perineural,
lymphatic and vascular invasion. Conﬁrmation of the diagnosis is
based on immunohistochemistry using a panel of markers: protein
S100 and melanocytic markers (HMB45, Melan-A, tyrosinase, MITF)
[13]. Epithelial cell markers are negative but several aberrant cases
have been reported [13].Fig. 2. Brown intracytoplasmic labelling of tumour cells with HMB45. The arrow
indicates a zone of intense labelling in the form of small grains.
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Table 1
American Joint Committee on cancer staging mucosal melanoma of the head and
neck, 7th edition.
Primary tumor (T)
T3 Mucosal disease
T4a Moderately advanced disease; tumor involving deep soft
tissue, cartilage, bone, or overlying skin
T4b Very advanced disease; tumor involving brain, dura, skull
base, lower cranial nerves (IX, X, XI, XII), masticator space,
carotid artery, prevertebral space, or mediastinal
structures
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases present
(M)
M0  No distant metastasis
M1  Distant metastasis present
Staging
Stage III T3, N0, M0
Stage IVA T4a, N0, M0ig. 3. MRI, T1-weighted sequence, coronal section, showing a tumour (deﬁne
hether it is a high- or intermediate-signal intensity and add arrows) of the nasal
avity and a homogeneous low-intensity right maxillary sinus.
ssential part of the local staging of the tumour. Computed tomo-
raphy of the facial bones and skull base is performed with axial and
oronal sections, with contiguous 1 mm thick (spiral acquisition) or
 maximum of 3 mm thick slices and dual window settings (bone
nd soft tissues). Intravenous iodinated contrast agent injection
llows enhancement of the tumour with respect to surrounding
issues. Three-dimensional (3D) reconstruction is particularly use-
ul when facial reconstruction is planned. The usual appearance
s that of an aggressive osteolytic tumour. Brain and facial MRI
rovides three-dimensional sections and usually comprises three
equences: T1, T1 post-gadolinium and T2. Malignant melanoma is
haracterized by heterogeneous contrast enhancement. According
o some authors, a spontaneous high-intensity signal on T1 with
 low-intensity signal on T2 would be characteristic of melanoma.
his unusual appearance, sometimes observed with other types of
umours (angiosarcoma, cylindroma and aesthesioneuroblastoma)
ppears to be related to the high melanin content and/or bleeding
nside the tumour [18,19]. T2-weighted MRI  can distinguish tumour
nvasion from paranasal sinus ﬂuid retention. Finally, MRI  is essen-
ial to deﬁne the anatomical relations of the tumour with the orbit
nd skull base and to detect any brain metastases (Figs. 3 and 4). Dis-
ant staging is based on chest, abdomen and pelvis CT and positron
ig. 4. MRI, T1-weighted with gadolinium administration sequence, axial section.
eterogeneous contrast enhancement of the tumour.T3–T4a, N1, M0
Stage IVB T4B, any N, M0
Stage IVC Any T, any N, M1
emission tomography (PET). This staging assessment looking for
metastases can be decisive in the choice of treatment and to assess
the value of certain cosmetically and functionally destructive forms
of radical surgery (orbital exenteration).
3.5. Classiﬁcation
The clinical and imaging assessment allows staging of the
melanoma in order to propose adapted treatment and to assess
the prognosis. Ballantyne’s classiﬁcation is the oldest classiﬁcation,
but does not take tumour size, tumour histology and local exten-
sion into account [20], as stage I is deﬁned as tumour conﬁned to the
original site, stage II is deﬁned as tumour with regional lymph node
metastases and stage III is deﬁned as tumour with distant metas-
tases. Use of this old classiﬁcation allows comparison of various
series [1], but it is now preferable to refer to the classiﬁcation estab-
lished by the American Joint Committee on Cancer (AJCC) [21,22].
The 7th edition of the AJCC classiﬁcation does not comprise stage
T1 and T2 in view of the systematically aggressive nature of these
melanomas. The proposed classiﬁcation comprising stage T3 and T4
tumours is more consistent with the local extension and the poor
prognosis of this disease (Table 1).
4. Treatment
4.1. Surgical treatment
A general consensus has been reached to consider surgery as
ﬁrst-line treatment [1,5,23]. The indication for surgery must take
into account the patient’s quality of life, due to the poor global
prognosis of these tumours. The treatment decision is generally
taken by an oncology multidisciplinary consultation based on the
staging assessment. Surgery is indicated as ﬁrst-line treatment and
in the case of local recurrence. The choice between an external
or an intranasal incision depends on the tumour size and site.
The choice of intranasal endoscopic surgery remains controver-
sial due to the difﬁculty of controlling surgical margins and should
be reserved for experienced teams [16]. It is indicated for strictly
intranasal tumours and under conditions of tumour resection that
are able to achieve the same cancer control results as via an exter-
nal approach. Craniofacial resection is the reference technique for
tumours situated in contact with or invading the skull base [16]. The
tumour must be widely resected with 1.5 to 2 cm negative surgical
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argins [17]. Margins are considered to be negative when they are
reater than or equal to 5 mm on deﬁnitive histological examina-
ion of the operative specimen. Systematic lymph node dissection
s not part of conventional surgical management and is only per-
ormed in the presence of clinically or radiologically pathological
ymph nodes [1]. The sentinel lymph node biopsy technique, used
n cutaneous melanoma, is currently under evaluation in mucosal
elanoma.
.2. Radiotherapy
Mucosal melanomas are generally considered to be poorly
adiosensitive. Melanomas are composed of cells with a high
ost-irradiation regenerative capacity. Radiotherapy is classically
ndicated in the presence of positive surgical margins, local
ecurrence, locally advanced tumour, or sometimes for pallia-
ive purposes or when the patient refuses surgery. The majority
f authors consider that adjuvant radiotherapy increases local
nd regional control without increasing survival independently of
umour stage [8,24–27]. There does not appear to be any signiﬁcant
urvival difference between patients treated by surgery alone and
atients treated by surgery and adjuvant radiotherapy [3,28]. How-
ver, the ﬁndings of these studies are controversial, as other teams
ave demonstrated the efﬁcacy of surgery and adjuvant radiothe-
apy on survival [1].
In particular, the development of new radiotherapy tech-
iques, such as intensity-modulated radiation therapy (IMRT) has
mproved the results obtained with conventional radiotherapy
specially on local and regional control with good local safety and
ow morbidity [29–31]. As a result of this progress, radiotherapy
s increasingly proposed systematically as part of the initial phase
f treatment as an adjuvant to surgery whether or not the surgical
argins are invaded [29,31].
.3. Chemotherapy
Chemotherapy is classically indicated for palliative treatment
r in metastatic patients [7]. However, some authors have pro-
osed multimodal ﬁrst-line treatment comprising chemotherapy
nd/or immunotherapy for the management of locally aggressive
orms [28,32]. A recent study highlighted the value of selective
ntraarterial chemotherapy [33]. Immunotherapy by interleukin
 or interferon alpha (IFN) either alone or in combination
ith chemotherapy and vaccination is currently under evaluation
34,35]. In metastatic disease or unresectable forms of cutaneous
elanoma, the chemotherapy strategy is designed according to the
resence or absence of V600 mutation [31,36]. Vemurafenib, a BRAF
rotein kinase inhibitor, is therefore reserved for the treatment of
dvanced melanoma associated with BRAF V600 mutation [31,37].
rials of vemurafenib and ipilimumab combination therapy are cur-
ently underway in patients with BRAF mutation. In the absence
f BRAF V600 mutation, treatment of these advanced, treatment-
efractory forms is based on the use of ipilimumab either alone
r in combination with standard chemotherapy (dacarbazine). The
ransposition of these recent data to the management of stage 4
ucosal melanoma of the nasal cavity and paranasal sinuses must
e considered in the light of progress of oncogenetics in these
ucosal forms.
However, the adverse effects of these treatments represent aonsiderable limiting factor for the management of patients with
ucosal melanoma of the nasal cavity and paranasal sinuses, who
re generally elderly with comorbidities contraindicating any form
f chemotherapy or immunotherapy.y, Head and Neck diseases 131 (2014) 365–369
5. Survival and prognosis
The 5-year overall survival of mucosal melanoma of the nasal
cavity and paranasal sinuses in the most recent series does not
exceed 40% (20%–40%) [5–8] and mean survival does not exceed
28 months (17–28 months) [4,27]. Local recurrences occur in about
50% of cases [3,27]. This high recurrence rate appears to be due to
the multifocal nature of the lesions, submucosal lymphatic spread
and the high rate of vascular invasion. Local recurrences are also
related to inadequate ﬁrst-line surgical resection. Local recurrences
are predictive of the presence of distant metastases [3,27]. The most
common metastatic sites are lungs, liver, bone and, more rarely,
brain and adrenal glands. Metastases are found in about 50% of
cases, sometimes during the course of the disease [27], while lymph
node metastases are found in 20 to 40% of cases [13,27].
Prognostic factors have been extensively studied in the litera-
ture by means of multivariate analyses. The quality of the initial
tumour resection with negative resection margins is the most
important prognostic criterion for tumours conﬁned to the nasal
cavity [6,17].
An advanced age at the time of diagnosis is a factor of poor prog-
nosis. The unfavourable age limit has been estimated to be 70 years
according to some authors [38] and 60 years according to others
[1,3], while age less than 50 years appears to be associated with a
better prognosis [3]. Tumour size greater than 3–4 cm is considered
to be a factor of poor prognosis [13,38]. An isolated septal tumour
is associated with good prognosis [6] in contrast with tumours of
the paranasal sinuses that have a very poor prognosis.
Ballantyne’s stage I has a better prognosis [1]. A high mitotic
index and a pseudopapillary and sarcomatoid architecture on
histological examination are factors of poor prognosis [4,13,39].
Some authors consider the presence of melanin and the level of
pigmentation to be factors of poor prognosis [4], while achromic
melanomas are usually considered to be associated with a poorer
prognosis [40].
6. Conclusion
Early diagnosis of mucosal melanoma of the nasal cavity is an
essential prognostic factor. The presence of unilateral symptoms,
such as epistaxis or nasal obstruction, in a patient over the age of
60 years must be considered to be suspicious. The diagnosis is based
on histological and immunohistochemical examination of a biopsy.
First-line treatment is based on wide surgical resection, possibly
completed by adjuvant radiotherapy. An initial complete resection
with healthy margins is a decisive factor for survival. The overall
prognosis of these tumours is very poor. Hopes for improvement of
survival are based on progress in radiotherapy techniques and cell
and gene therapy that are currently under evaluation.
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